
Johnson & Johnson gains 28% YTD but trades at premium; hold rating advised amid risks and strong pharma growth.
Johnson & Johnson has delivered a strong 28% total return year-to-date in 2026, outperforming major benchmarks like the S&P 500 ETF and healthcare sector ETF XLV. Despite solid second-quarter results and an upgraded full-year 2026 guidance driven by ...

